» Articles » PMID: 1666303

Complementation Between Urokinase-producing and Receptor-producing Cells in Extracellular Matrix Degradation

Overview
Journal Cell Regul
Date 1991 Oct 1
PMID 1666303
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The respective roles of urokinase plasminogen activator (u-PA) and the u-PA receptor in extracellular matrix degradation was investigated. Human pro-u-PA and the human u-PA receptor were expressed independently by two different mouse LB6 cell lines. The matrix degradation capacity of these cell lines individually or in coculture was studied. Although pro-u-PA-producing cells alone degrade the matrix in the presence of plasminogen, u-PA-receptor producing cells do not. Cocultivation of a small fraction of pro-u-PA-producing cells with the receptor-producing cells increases the rate of matrix degradation at least threefold. By immunoprecipitation it was shown that cocultivation of the two cell lines increases the conversion of the inactive pro-u-PA to the active two chain u-PA. The enhancement of matrix degradation and of pro-u-PA activation requires actual binding of pro-u-PA to its receptor because it is inhibited by u-PA-receptor antagonists. The u-PA receptor must be cell associated, as binding of pro-u-PA to a receptor solubilized from the cell surface with phosphatidyl-inositol specific phospholipase C did not enhance the activation of pro-u-PA in the presence of plasminogen. The finding that activity of u-PA is enhanced when it is bound to its receptor, even when the receptor is produced by a different cell, might have important implications for the mechanisms of u-PA-induced extracellular proteolysis in vivo.

Citing Articles

Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.

Li D, Liu S, Shan H, Conti P, Li Z Theranostics. 2013; 3(7):507-15.

PMID: 23843898 PMC: 3706694. DOI: 10.7150/thno.5557.


The effect of suramin on the resorption of bovine nasal cartilage.

Lewis C, Frazer A, Russell R, Bunning R Inflammopharmacology. 2007; 7(4):387-400.

PMID: 17657441 DOI: 10.1007/s10787-999-0032-x.


Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Lee K, Hyun M, Kim J Clin Exp Metastasis. 2003; 20(6):499-505.

PMID: 14598883 DOI: 10.1023/a:1025824816021.


Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation.

Bryson H, Buttle D, Kozaci L, Johnatty R, Bunning R Biochem J. 2000; 345 Pt 3:495-501.

PMID: 10642507 PMC: 1220783.


Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.

Harvey S, Sait S, Xu Y, Bailey J, Penetrante R, Markus G Am J Pathol. 1999; 155(4):1115-20.

PMID: 10514394 PMC: 1867004. DOI: 10.1016/S0002-9440(10)65214-5.


References
1.
Vassalli J, Baccino D, Belin D . A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100(1):86-92. PMC: 2113459. DOI: 10.1083/jcb.100.1.86. View

2.
Reich R, Thompson E, Iwamoto Y, Martin G, Deason J, Fuller G . Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 1988; 48(12):3307-12. View

3.
Stoppelli M, Corti A, Soffientini A, Cassani G, Blasi F, Assoian R . Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A. 1985; 82(15):4939-43. PMC: 390473. DOI: 10.1073/pnas.82.15.4939. View

4.
OSSOWSKI L, Reich E . Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983; 35(3 Pt 2):611-9. DOI: 10.1016/0092-8674(83)90093-4. View

5.
Gorman C, Moffat L, Howard B . Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982; 2(9):1044-51. PMC: 369897. DOI: 10.1128/mcb.2.9.1044-1051.1982. View